Genomic Clinical Decision Support Market (2026-2036)

The growth of this market is mainly driven by the rapid growth of comprehensive genomic profiling in oncology and the need to match patients to targeted therapies and clinical trials, the expansion of pharmacogenomic testing and the integration of pharmacogenomic guidance into prescribing workflows, the increasing complexity of genomic results and the number of actionable biomarkers, guidelines, and approved therapies that clinicians must interpret, and the integration of genomic data into electronic health records (EHRs). In addition, the clarification of regulatory frameworks for CDS software, the application of artificial intelligence (AI) and large language models to genomic interpretation and evidence curation, the growth of national genomic medicine programs, and the shortage of genetics specialists relative to the number of patients receiving genomic tests are further supporting the growth of this market.

The Genomic Clinical Decision Support Market, also referred to as the genomic CDS market, genomics-enabled clinical decision support market, or precision medicine decision support market, comprises the software, knowledge bases and content, and services that translate genomic test results into clinical recommendations for healthcare providers at the point of care. The market includes oncology decision support for matching tumor genomic alterations to approved therapies, guidelines, and clinical trials; pharmacogenomic CDS that generates drug-gene alerts and dosing recommendations in prescribing systems; decision support for hereditary cancer, cardiovascular, rare, and inherited diseases, including risk management and cascade testing recommendations; reproductive and prenatal decision support; genomic modules within EHRs that store discrete genomic results and trigger alerts; curated genomic knowledge bases of variant, biomarker, therapy, and guideline evidence; and implementation, integration, and curation services. The market ecosystem extends from CDS software and knowledge base providers, EHR vendors, and genomic testing companies to hospitals and health systems, cancer centers, primary care and specialty practices, clinical laboratories, pharmacies, payers, and national genomic medicine programs.

Genomic medicine creates a decision problem for clinicians. Comprehensive genomic profiling of tumors can identify hundreds of alterations, each of which may be linked to approved therapies, investigational drugs, clinical trials, and guidelines that change frequently. Pharmacogenomic results affect the choice and dosing of many commonly prescribed drugs, such as antidepressants, statins, anticoagulants, antiplatelet agents, and proton pump inhibitors, and these results need to be available every time a relevant drug is prescribed, often years after the test. Most clinicians are not genetics specialists, and the number of patients receiving genomic tests far exceeds the number of genetic counselors and clinical geneticists. Genomic CDS addresses this gap by delivering curated, actionable recommendations within clinical workflows.

Oncology is the largest market. Genomic testing companies, cancer centers, and CDS providers use curated knowledge bases to match tumor alterations to therapies and trials and to generate clinician-facing reports, and health systems increasingly integrate these results into EHRs. In the second quarter of 2026, Tempus AI, Inc. reported revenue of USD 382.5 million, up 22% year over year, with oncology testing volume up 31% and Data and Applications revenue of USD 93.2 million, up 28%, and raised its full-year 2026 revenue guidance to USD 1.595-1.605 billion. The growth of oncology testing volumes, the expanding number of biomarker-driven therapies, and the use of molecular residual disease testing are increasing demand for oncology decision support.

Pharmacogenomics is the fastest-growing area. In England, the NHS PROGRESS pharmacogenomics trial expanded to 20 general practices, using the PROGRESSRx tool to integrate pharmacogenomic results into prescribing systems and display guidance at the point of prescribing; 93% of participants carried a clinically relevant variant in at least one of the four study genes, about 80% of the guidance was followed, and 35% of participants had a change to their prescription. Health systems in the U.S. and Europe are implementing preemptive pharmacogenomic testing, in which a panel of genes is tested once and results are stored in the EHR to trigger alerts whenever relevant drugs are prescribed, and guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) provide the evidence base. EHR vendors, such as Epic Systems with its Genomics module, are enabling health systems to store discrete genomic results and build CDS alerts.

The regulatory environment for CDS software is becoming clearer. In January 2026, the U.S. Food and Drug Administration (FDA) published revised guidance on clinical decision support (CDS) software, superseding its 2022 guidance, clarifying which CDS functions are exempt from device regulation under the 21st Century Cures Act, and indicating that certain CDS that provides a single clinically appropriate recommendation for review by a healthcare provider, based on medical record information and clinical guidelines, may fall outside FDA regulation if it meets all statutory criteria. At the same time, genomic CDS that analyzes data to provide diagnostic or treatment recommendations without allowing clinicians to independently review the basis may remain subject to device regulation, and in Europe, software that provides diagnostic or therapeutic information may be regulated under the In Vitro Diagnostic Regulation or the Medical Device Regulation.

The market includes EHR vendors such as Epic Systems and Oracle Health; genomic interpretation and CDS providers such as QIAGEN, Illumina, Roche (including Foundation Medicine and the navify portfolio), SOPHiA GENETICS, and Velsera; and AI-driven precision medicine companies such as Tempus AI. These companies compete on the quality, breadth, and currency of curated knowledge bases, integration with EHRs and laboratory systems, clinical trial matching, regulatory compliance, ease of use for clinicians, and evidence of clinical utility.

At the same time, the market faces challenges, including the difficulty of integrating genomic data into EHRs in structured form, alert fatigue among clinicians, the cost and effort of maintaining up-to-date knowledge bases, limited reimbursement for pharmacogenomic testing and for decision support itself, and the need for evidence that genomic CDS improves outcomes. As a result, companies that combine curated and continuously updated knowledge, seamless EHR integration, clinician-friendly workflows, AI-assisted curation, and evidence of clinical and economic value are expected to capture the largest share of growth over the forecast period.